Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis

Alizadeh, Narges; Nori, Hamed Monadi; Golchi, Javad; Eshkevari, Shahriar Sadr; Leyli, Ehsan Kazemnezhad; Darjani, A

doi:10.1155/2014/705402

Cited by 11 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SD is characterised by sharply defined erythematous patches and plaques with greasy-looking, yellowish scales on seborrheic areas such as the scalp, face, upper trunk, and flexures. The growth of Malassezia species was suggested as an important pathogenic factor of SD23, as demonstrated by studies that showed that SD was improved by the use of antifungal agents45. Current treatment options include antifungal drugs, anti-inflammatory agents (steroids, calcineurin inhibitors, and lithium salts), keratolytic agents, and phototherapy.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study

et al. 2016

View full text Add to dashboard Cite

BackgroundSeborrheic dermatitis (SD) is a multifactorial disease; Malassezia species play an important role in its pathogenesis.ObjectiveWe aimed to determine whether a cream containing climbazole/piroctone olamine (C/P cream), antifungal agents with expected efficacy against Malassezia species, could improve SD symptoms.MethodsWe instructed 24 patients with mild-to-moderate SD to apply the C/P cream and emollient cream on the right and left sides of the face, respectively, every morning and evening for 4 weeks. The casual sebum level (measured with Sebumeter®; Courage & Khazaka Electronic GmbH, Germany) and the extent of erythema (measured with Mexameter®; Courage & Khazaka Electronic GmbH) on the face were measured at baseline and after 4 weeks. The minimal inhibitory concentration (MIC) was determined to demonstrate the antifungal activity of the C/P cream.ResultsThe casual sebum level and erythema were measured at week 4, and the median values demonstrated a quantitative improvement on the C/P cream-treated right side of the face compared to the emollient cream-treated left side. For the C/P cream, the MICs were 0.625, 5, 0.625, and 2.5 mg/ml for Malassezia restricta, M. globosa, M. sympodialis, and M. slooffiae, respectively.ConclusionBased on the reduced casual sebum level and extent of erythema, the antifungal activity of C/P cream against Malassezia species seems useful for the treatment of mild to moderate SD.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…in infants, present in the normal skin microbiota, 134 , 135 explaining the option of topical treatment of SD with antifungals. 136 Topical immunomodulators and corticosteroids are also used 137 ; in extensive conditions resistant to topical treatment, systemic treatment with corticosteroids or isotretinoin may be necessary. This drug is a second-line treatment, used in clinical practice, but there is no definition of dose and duration of treatment.…”

Section: Resultsmentioning

confidence: 99%

Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology

Bagatin

Costa

Rocha

et al. 2020

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Background Isotretinoin is a synthetic retinoid, derived from vitamin A, with multiple mechanisms of action and highly effective in the treatment of acne, despite common adverse events, manageable and dose-dependent. Dose-independent teratogenicity is the most serious. Therefore, off-label prescriptions require strict criteria. Objective To communicate the experience and recommendation of Brazilian dermatologists on oral use of the drug in dermatology. Methods Eight experts from five universities were appointed by the Brazilian Society of Dermatology to develop a consensus on indications for this drug. Through the adapted DELPHI methodology, relevant elements were listed and an extensive analysis of the literature was carried out. The consensus was defined with the approval of at least 70% of the experts. Results With 100% approval from the authors, there was no doubt about the efficacy of oral isotretinoin in the treatment of acne, including as an adjunct in the correction of scars. Common and manageable common adverse events are mucocutaneous in nature. Others, such as growth retardation, abnormal healing, depression, and inflammatory bowel disease have been thoroughly investigated, and there is no evidence of a causal association; they are rare, individual, and should not contraindicate the use of the drug. Regarding unapproved indications, it may represent an option in cases of refractory rosacea, severe seborrheic dermatitis, stabilization of field cancerization with advanced photoaging and, although incipient, frontal fibrosing alopecia. For keratinization disorders, acitretin performs better. In the opinion of the authors, indications for purely esthetic purposes or oil control are not recommended, particularly for women of childbearing age. Conclusions Approved and non-approved indications, efficacy and adverse effects of oral isotretinoin in dermatology were presented and critically evaluated.

show abstract

“…We did not see this index as objective, as there is no way of knowing what weight different symptoms are given in such sum scores. The following studies were excluded because they used such a composite symptom score: Amos 1994 ; Boyle 1986 ; Brown 1990 ; Cauwenbergh 1986 ; Comert 2007 ; Ermosilla 2005 ; Koca 2003 ; Kozlowska 2007 ; Peter 1995 ; Pierard-Franchimont 2002b ; Vena 2005. This exclusion was not prespecified in the protocol.…”

Section: Resultsmentioning

confidence: 99%

Topical antifungals for seborrhoeic dermatitis

Okokon

Verbeek

Ruotsalainen

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Seborrhoeic dermatitis is a chronic inflammatory skin condition that is distributed worldwide. It commonly affects the scalp, face and flexures of the body. Treatment options include antifungal drugs, steroids, calcineurin inhibitors, keratolytic agents and phototherapy. Objectives To assess the effects of antifungal agents for seborrhoeic dermatitis of the face and scalp in adolescents and adults. A secondary objective is to assess whether the same interventions are effective in the management of seborrhoeic dermatitis in patients with HIV/AIDS. Search methods We searched the following databases up to December 2014: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 11), MEDLINE (from 1946), EMBASE (from 1974) and Latin American Caribbean Health Sciences Literature (LILACS) (from 1982). We also searched trials registries and checked the bibliographies of published studies for further trials. Selection criteria Randomised controlled trials of topical antifungals used for treatment of seborrhoeic dermatitis in adolescents and adults, with primary outcome measures of complete clearance of symptoms and improved quality of life. Data collection and analysis Review author pairs independently assessed eligibility for inclusion, extracted study data and assessed risk of bias of included studies. We performed fixed-effect meta-analysis for studies with low statistical heterogeneity and used a random-effects model when heterogeneity was high. Main results We included 51 studies with 9052 participants. Of these, 45 trials assessed treatment outcomes at five weeks or less after commencement of treatment, and six trials assessed outcomes over a longer time frame. We believe that 24 trials had some form of conflict of interest, such as funding by pharmaceutical companies. Among the included studies were 12 ketoconazole trials (N = 3253), 11 ciclopirox trials (N = 3029), two lithium trials (N = 141), two bifonazole trials (N = 136) and one clotrimazole trial (N = 126) that compared the effectiveness of these treatments versus placebo or vehicle. Nine ketoconazole trials (N = 632) and one miconazole trial (N = 47) compared these treatments versus steroids. Fourteen studies (N = 1541) compared one antifungal versus another or compared different doses or schedules of administration of the same agent versus one another. Ketoconazole Topical ketoconazole 2% treatment showed a 31% lower risk of failed clearance of rashes compared with placebo (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.59 to 0.81, eight studies, low-quality evidence) at four weeks of follow-up, but the effect on side effects was uncertain because evidence was of very low quality (RR 0.97, 95% CI 0.58 to 1.64, six studies); heterogeneity between studies was substantial ...

show abstract

Comparison the Efficacy of Fluconazole and Terbinafine in Patients with Moderate to Severe Seborrheic Dermatitis

Cited by 11 publications

References 8 publications

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study

Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology

Topical antifungals for seborrhoeic dermatitis

Contact Info

Product

Resources

About